Joshua M. Hare, MD, the cofounder and chief science officer of Longeveron, discussed updated data from the phase 2a CLEAR MIND study. Longeveron's Lomecel-B is an allogeneic bone marrow-derived medicinal signaling cell (MSC) formulation. At the 2024 Alzheimer’s Association International Conference (AAIC), held July 28-August 2nd in Philadelphia, Pennsylvania, the company reported data from the phase 2a CLEAR MIND trial (NCT05233774), which evaluated Lomecel-B for the treatment of Alzheimer disease (AD).